Kirkland Advises GTCR on Acquisition of Surmodics for Approximately $627 Million
Kirkland & Ellis represented GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology, on its definitive agreement to acquire Surmodics, Inc., a provider of medical device and in vitro diagnostic technologies to the healthcare industry. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million. The transaction is expected to close in the second half of calendar year 2024, subject to customary closing conditions, including approval by Surmodics shareholders and required regulatory approval.
Read the transaction press release
The Kirkland team was led by corporate partners Christopher Thomas and Neil Vohra, and included corporate partners Sanford Perl, Michael Weed, Rachael Coffey and associates Katherine Kennedy and Jessica Lowe; debt finance partners Tom Dobleman and Patrick Loughery; capital markets partner Rachel Sheridan; tax partner Polina Liberman; and healthcare and life sciences regulatory partners Dennis Williams and Kate Hardey.
